Biomedical Sciences, Dstl Porton Down, Salisbury SP4 0JQ, UK.
Centre for Biomolecular Sciences, University of Nottingham, University Park, Nottingham NG7 2RD, UK.
J Med Microbiol. 2012 Jul;61(Pt 7):889-894. doi: 10.1099/jmm.0.039180-0. Epub 2012 Feb 9.
Vaccine development has played a hugely important role in combating infectious disease. Despite this success, there is still a great need for new vaccines and these are emerging far more slowly than we would wish. Despite the massive expansion in understanding of immune responses to infection, research is often hindered by a lack of understanding of the immune responses required specifically for protection, or by a lack of approved adjuvants and delivery systems to induce the required responses. In addition, the financial commitment required to license new vaccines is significant, and the more lucrative markets are often not those with the greatest need. In this review, we discuss many of the hurdles that new vaccines must overcome in order to reduce morbidity and mortality, and some of the initiatives that are being attempted to supply new vaccines to those that need them most.
疫苗的研发在对抗传染病方面发挥了巨大的作用。尽管取得了这一成功,但我们仍然非常需要新的疫苗,而这些疫苗的出现速度却比我们希望的要慢得多。尽管人们对感染引起的免疫反应有了大量的了解,但由于缺乏对特定于保护所需的免疫反应的了解,或者缺乏经过批准的佐剂和传递系统来诱导所需的反应,研究往往受到阻碍。此外,获得新疫苗的许可所需的财务承诺是巨大的,而利润更高的市场往往不是那些最需要的市场。在这篇综述中,我们讨论了新疫苗必须克服的许多障碍,以降低发病率和死亡率,以及正在尝试采取的一些措施,以便向最需要的人提供新疫苗。